Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Tools & Techniques Immunology, Microbiology, Diagnostics & prognostics

Inside Intestinal Disease

Inflammatory bowel diseases (IBD) are relapsing and remitting chronic conditions of the gut that have a major impact on patients’ quality of life. Current therapeutic approaches aim to reduce symptoms – but their effectiveness varies, and patients may develop tolerances to the drugs. As such, it’s really important to have ways of assessing disease activity to better manage patients. Identifying microbial alterations associated with IBD could provide a diagnostic tool that enables us to spot disease earlier and minimize damage. It also contributes to better understanding of the underlying mechanisms associated with disease pathogenesis, allowing the design of improved therapeutic strategies.

The first line of defense against potential microbial invasion in the gut is a viscous layer of mucus that covers the intestinal epithelium. In our study (1), we excised the relevant mouse gut segment, opened it up longitudinally, and washed to remove residual luminal contents before scraping off the mucus for further testing. It’s a difficult procedure to translate into human studies because most patients undergo routines such as colonic lavage before they are biopsied, resulting in samples that may not fully replicate the in situ bacterial communities. However, an in situ method of mucus sampling without colonic lavage that can be performed in the clinic was recently developed (2), so in the future it should be easier to get patient mucus samples. Testing would involve either qPCR or a form of protein analysis, such as ELISA.

Given that differences in microbiota composition start in the mucus before the onset of inflammation, our findings provide a framework for identifying temporal and spatial changes in the most relevant microbial communities that underpin subsequent development of IBD. Now, we are exploring whether the shifts in mucus microbial communities correlate with changed function and altered metabolite profiles. We are also developing methodologies to analyze microbial networks to develop better predictive strategies.

Receive content, products, events as well as relevant industry updates from The Translational Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. M Glymenaki et al., “Compositional changes in the gut mucus microbiota precede the onset of colitis-induced inflammation”, Inflamm Bowel Dis, 23, 912–922 (2017). PMID: 28498157.
  2. Origin Sciences, “Oricol™ Sample Collection” (2015). Available at: bit.ly/2sXKFDl. Accessed July 14, 2017.
About the Author
Sheena Cruickshank

Sheena Cruickshank is a Senior Lecturer in Immunology at the Faculty of Biology, Medicine and Health, University of Manchester, UK.

Related Solutions
Biomarker Optimization on LabSat® Research

| Contributed by Epredia

One Week to One Day

| Contributed by Epredia

Most Popular
Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register